Ascletis Pharma Inc
HKEX:1672

Watchlist Manager
Ascletis Pharma Inc Logo
Ascletis Pharma Inc
HKEX:1672
Watchlist
Price: 1.77 HKD -3.8% Market Closed
Market Cap: 1.7B HKD
Have any thoughts about
Ascletis Pharma Inc?
Write Note

Intrinsic Value

Ascletis Pharma Inc's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one Ascletis Pharma Inc stock under the Base Case scenario is 0.71 HKD. Compared to the current market price of 1.77 HKD, Ascletis Pharma Inc is Overvalued by 60%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
0.71 HKD
Overvaluation 60%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Ascletis Pharma Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for Ascletis Pharma Inc cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about Ascletis Pharma Inc?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Ascletis Pharma Inc

Provide an overview of the primary business activities
of Ascletis Pharma Inc.

What unique competitive advantages
does Ascletis Pharma Inc hold over its rivals?

What risks and challenges
does Ascletis Pharma Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ascletis Pharma Inc.

Provide P/S
for Ascletis Pharma Inc.

Provide P/E
for Ascletis Pharma Inc.

Provide P/OCF
for Ascletis Pharma Inc.

Provide P/FCFE
for Ascletis Pharma Inc.

Provide P/B
for Ascletis Pharma Inc.

Provide EV/S
for Ascletis Pharma Inc.

Provide EV/GP
for Ascletis Pharma Inc.

Provide EV/EBITDA
for Ascletis Pharma Inc.

Provide EV/EBIT
for Ascletis Pharma Inc.

Provide EV/OCF
for Ascletis Pharma Inc.

Provide EV/FCFF
for Ascletis Pharma Inc.

Provide EV/IC
for Ascletis Pharma Inc.

Show me price targets
for Ascletis Pharma Inc made by professional analysts.

What are the Revenue projections
for Ascletis Pharma Inc?

How accurate were the past Revenue estimates
for Ascletis Pharma Inc?

What are the Net Income projections
for Ascletis Pharma Inc?

How accurate were the past Net Income estimates
for Ascletis Pharma Inc?

What are the EPS projections
for Ascletis Pharma Inc?

How accurate were the past EPS estimates
for Ascletis Pharma Inc?

What are the EBIT projections
for Ascletis Pharma Inc?

How accurate were the past EBIT estimates
for Ascletis Pharma Inc?

Compare the revenue forecasts
for Ascletis Pharma Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ascletis Pharma Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ascletis Pharma Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ascletis Pharma Inc compared to its peers.

Compare the P/E ratios
of Ascletis Pharma Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Ascletis Pharma Inc with its peers.

Analyze the financial leverage
of Ascletis Pharma Inc compared to its main competitors.

Show all profitability ratios
for Ascletis Pharma Inc.

Provide ROE
for Ascletis Pharma Inc.

Provide ROA
for Ascletis Pharma Inc.

Provide ROIC
for Ascletis Pharma Inc.

Provide ROCE
for Ascletis Pharma Inc.

Provide Gross Margin
for Ascletis Pharma Inc.

Provide Operating Margin
for Ascletis Pharma Inc.

Provide Net Margin
for Ascletis Pharma Inc.

Provide FCF Margin
for Ascletis Pharma Inc.

Show all solvency ratios
for Ascletis Pharma Inc.

Provide D/E Ratio
for Ascletis Pharma Inc.

Provide D/A Ratio
for Ascletis Pharma Inc.

Provide Interest Coverage Ratio
for Ascletis Pharma Inc.

Provide Altman Z-Score Ratio
for Ascletis Pharma Inc.

Provide Quick Ratio
for Ascletis Pharma Inc.

Provide Current Ratio
for Ascletis Pharma Inc.

Provide Cash Ratio
for Ascletis Pharma Inc.

What is the historical Revenue growth
over the last 5 years for Ascletis Pharma Inc?

What is the historical Net Income growth
over the last 5 years for Ascletis Pharma Inc?

What is the current Free Cash Flow
of Ascletis Pharma Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ascletis Pharma Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Ascletis Pharma Inc

Balance Sheet Decomposition
Ascletis Pharma Inc

Current Assets 2.1B
Cash & Short-Term Investments 2.1B
Receivables 12.6m
Other Current Assets 23.1m
Non-Current Assets 160.7m
Long-Term Investments 70.8m
PP&E 65.2m
Intangibles 24.4m
Other Non-Current Assets 269k
Current Liabilities 86.8m
Accounts Payable 464k
Other Current Liabilities 86.3m
Non-Current Liabilities 9m
Long-Term Debt 4.3m
Other Non-Current Liabilities 4.8m
Efficiency

Earnings Waterfall
Ascletis Pharma Inc

Revenue
10.1m CNY
Cost of Revenue
-22.7m CNY
Gross Profit
-12.6m CNY
Operating Expenses
-267.6m CNY
Operating Income
-280.2m CNY
Other Expenses
21.7m CNY
Net Income
-258.5m CNY

Free Cash Flow Analysis
Ascletis Pharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

Ascletis Pharma Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

Positive Revenue Growth Forecast
Negative 1-Year Revenue Growth
Negative ROE
Negative Gross Profit
20/100
Profitability
Score

Ascletis Pharma Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Ascletis Pharma Inc's solvency score is 72/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
72/100
Solvency
Score

Ascletis Pharma Inc's solvency score is 72/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Ascletis Pharma Inc

Wall Street analysts forecast Ascletis Pharma Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Ascletis Pharma Inc is 2.03 HKD with a low forecast of 2.01 HKD and a high forecast of 2.09 HKD.

Lowest
Price Target
2.01 HKD
14% Upside
Average
Price Target
2.03 HKD
15% Upside
Highest
Price Target
2.09 HKD
18% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Ascletis Pharma Inc?

Click here to dive deeper.

Dividends

Ascletis Pharma Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for Ascletis Pharma Inc is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Ascletis Pharma Inc Logo
Ascletis Pharma Inc

Country

China

Industry

Biotechnology

Market Cap

1.8B HKD

Dividend Yield

0%

Description

Ascletis Pharma, Inc. operates as biotechnology firm to test the waters. The company is headquartered in Hangzhou, Zhejiang and currently employs 266 full-time employees. The company went IPO on 2018-08-01. The firm is focused on three therapeutic areas, including anti-viral, cancer and fatty liver disease. The Company’s main products include drugs against hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV).

Contact

ZHEJIANG
Hangzhou
12F, Tower D, Hangzhou Bay Information Port, No.198, Qidi Road, Xiaoshan District
www.ascletis.com

IPO

2018-08-01

Employees

266

Officers

Founder, Chairman & CEO
Dr. Jinzi Jason Wu Ph.D.
Senior VP of Operations & Executive Director
Ms. Hejingdao Wu
Senior Vice President of Clinical Development Operations
Ms. Yuemei Yan
Senior Consultant & Head of Discovery
Dr. Kristjan Sigurdur Gudmundsson
Senior Consultant & Chief Medical Advisor
Dr. George Zhengzhi Hill
Chief Business Officer
Mr. John P. Gargiulo M.B.A.

See Also

Discover More
What is the Intrinsic Value of one Ascletis Pharma Inc stock?

The intrinsic value of one Ascletis Pharma Inc stock under the Base Case scenario is 0.71 HKD.

Is Ascletis Pharma Inc stock undervalued or overvalued?

Compared to the current market price of 1.77 HKD, Ascletis Pharma Inc is Overvalued by 60%.

Back to Top